EL7.AI
StocksMedium•8 October 2026•
4 min read

Humana shares jump 15% after Medicare plan ratings improve for 2027

Key Facts

1Humana said 95% of its Medicare Advantage members were enrolled in plans rated four stars or higher for 2027.
2Humana shares rose 15% during trading on Friday, October 9, 2026, according to Reuters.
3Evercore ISI analyst Elizabeth Anderson estimated Humana's potential bonuses in 2028 at about $4.8 billion.
4Humana said 42% of its Medicare Advantage members were enrolled in plans rated 4.5 stars for 2027.

Humana shares rose 15% during trading on Friday, October 9, 2026, after the 2027 Medicare Advantage ratings showed an improvement in the health insurer's plans, Reuters reported. The company said in a statement issued the same day that 95% of its program members were enrolled in plans rated four stars or higher. The result exceeded JPMorgan's expectations, which had put the share of members in highly rated plans at between 60% and 70%, according to the news agency. The company's Friday disclosure came in an update following the release of the ratings, setting out the proportion of its members enrolled in highly rated plans. Reuters linked the share price gain to the improved ratings, which determine the company's eligibility for quality bonuses at a later date.

The improvement marks a recovery after the share of Humana members in bonus-eligible plans fell to 20% in the 2026 ratings, according to Investing's coverage of a Cantor Fitzgerald analysis. That share stood at 94% in the 2024 ratings before declining in the subsequent period covered by the analysis. The latest result thus takes the company above its previous share in eligible plans, following the decline recorded in earlier ratings. The recovery also followed legal pressures, as Humana lost a lawsuit in October of the previous year challenging the methodology used to calculate the 2025 ratings, Reuters reported. Across the sector, the Centers for Medicare & Medicaid Services said about 71% of enrollees in Medicare Advantage with prescription drug coverage were in contracts that would receive four stars or higher for 2027, weighted by membership.

Humana said its ratings gains spanned all categories of measures used in the assessment, describing the result as a "meaningful improvement in performance across all measure categories." In its membership breakdown, the company said 42% of its Medicare Advantage members were enrolled in plans awarded a 4.5-star rating for 2027. That places those members in plans above the four-star level the company used to present its overall improvement. Humana also reported in its ratings statement an increase of 534000 in the number of members who completed an annual wellness visit compared with the previous year. The company's announcement brought together improved assessment results across measure categories and an increase in the number of members completing those preventive visits.

The financial impact of the new ratings relates to 2028, as the Centers for Medicare & Medicaid Services confirmed they would affect Medicare Advantage quality bonuses for that year. Evercore ISI analyst Elizabeth Anderson estimated that Humana could receive $4.8 billion in bonuses in 2028, according to Reuters. Anderson's estimate concerns bonus payments the company could receive, while Baird analysts linked the size of the earnings benefit to the accompanying spending decisions. Baird analysts said that benefit would depend on reinvestment in member benefits and arrangements with healthcare providers. According to their analysis, the allocation of funds to member benefits and provider relationships helps determine how much of the ratings improvement translates into Humana's earnings.

In a filing with the U.S. Securities and Exchange Commission, Humana outlined how it intended to use the expected benefit from its ratings outperformance in 2028. It said the benefit would be used for "one-time investments and returning capital to shareholders," identifying the two uses it expects. The company's stated approach combines allocating funds for investment with returning capital to its shareholders, as part of a benefit it links to the new ratings results. Before the October announcement, Humana had reaffirmed its adjusted earnings per share guidance for fiscal 2026 when it released its second-quarter results. At the time, the company set the floor for that guidance at "at least $9.00" per share as part of its adjusted earnings outlook for that year.

On the calendar following the ratings announcement, open enrollment begins on October 15, 2026, according to the Centers for Medicare & Medicaid Services. The period runs through December 7, 2026, making it the enrollment window following publication of next year's plan ratings. Humana will then hold a virtual investor update on December 10, 2026, according to the date set out in its filing with the U.S. Securities and Exchange Commission. The company said the update would review progress against its previously announced earnings growth framework. That timing places the company's review of its performance before investors after the end of open enrollment, within the sequence of dates announced following the ratings improvement.

Open on chart